Pune, India, March 02, 2021 (GLOBE NEWSWIRE) — According to the report, Breast Cancer Therapeutics market size is projected to reach USD 55.27 Billion by 2027. Breast Cancer Therapeutics Market was worth USD 21.58 billion in 2019 and will exhibit a CAGR of 13.1% during the forecast period. The global breast cancer therapeutics market is set to gain impetus from the ongoing research and developments to come up with state-of-the-art drugs.

Nowadays, several renowned companies are constantly launching new breast cancer therapeutics worldwide. Most of these drugs are meant for the treatment of those types of breast cancers that were previously untreatable or the available drugs were not successful for providing positive outcomes. These factors are expected to accelerate the breast cancer therapeutics market growth in the forthcoming years. However, certain severe reactions can come up while undergoing this type of cancer therapeutics, such as targeted therapies. Patients can suffer from nausea, fatigues, rashes, gastrointestinal problems, or high blood pressure. These may hinder growth.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/breast-cancer-therapeutics-market-100163


COVID-19 Pandemic to Affect Growth Moderately as Cancer Requires Immediate Attention

Based on therapy, the hormonal therapy segment generated 8.3% in terms of the breast cancer therapeutics market share in 2019. It is likely to exhibit lower growth in the coming years on account of the rising availability of their generic equivalents.

Regionally, North America procured USD 10.34 billion in 2019 in terms of revenue. The rising prevalence of breast cancer, presence of numerous providers of breast cancer therapeutics, and the surging awareness of this condition are expected to augment growth in this region. The American Cancer Society, for instance, declared that the U.S. is set to experience around 276,480 new cases of invasive breast cancer in 2020.

Europe, on the other hand, is likely to retain its second position fueled by the high demand for advanced and sophisticated breast cancer therapeutics. In Asia Pacific, the market would …

Full story available on Benzinga.com